Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis and Dimitri P. Mikhailidis Pages 2723 - 2725 ( 3 )
In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications [1]. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier review [1] based on recently published data.
IMPROVE-IT, diabetes mellitus, cancer, statins, new onset diabetes, ezetimibe.
, , , Department of Clinical Biochemistry, Royal Free Hospital Campus, University College Medical School, University College London (UCL), Pond Street, London NW3 2QG, UK.